Abstract 2336P
Background
Epithelial-mesenchymal transition (EMT) is one of the major molecular mechanisms inducing tumor invasion and metastasis. Various MicroRNAs (miRNAs) have been shown to be involved in EMT. MiR-155 is consistently up-regulated in non-small cell lung cancer and is associated with poor overall survival. Whether miR-155 regulates EMT in lung cancer cells remains unclear.
Methods
We first transfected plasmid containing miR-155 into H1299 and A549 cells and established H1299-miR-155 and A549-miR-155 cells. Western blotting was done to demonstrate E-cadherin, vimentin, and Quaking (QKI) expression in H1299-miR-155 and A549-miR-155 cells. Invasion and migration assay were performed in H1299-miR-155 and A549-miR-155 cells. We then constructed p-mcherry plasmids that contain miR-155 and a p-Luc-QKI-3’UTR reporter plasmid. Luciferase assay was done to demonstrate whether miR-155 binds to the QKI 3’UTR.
Results
Quantitative RT-PCR showed that QKI expression was downregulated in H1299-miR-155 and A549-miR-155 cells. Western Blotting showed decreased E-cadherin and increased vimentin expression in H1299 and A549 cells after miR-155 transfection. Western blotting also showed decreased QKI expression in H1299 and A549 cells after miR-155 transfection. Migration assay showed that the number of migrated cells significantly increased after miR-155 transfection in H1299 and A549 cells. Invasion assay showed that the number of invaded cells also significantly increased after miR-155 transfection in H1299 and A549 cells. We constructed p-mcherry plasmids that contain miR-155 and a p-Luc-QKI-3’UTR reporter plasmid. Luciferase assay showed that miR-155 represses the activity of p-Luc-QKI-3’UTR. We then mutated the miR-155 binding site in the QKI 3’UTR to confirm that repression of the mRNA levels is induced by the binding of miR-155 to the QKI 3’UTR.
Conclusions
MiR-155 overexpression regulates EMT through repressing QKI in lung cancer cells. Repression of QKI is induced by the binding of miR-155 to the QKI 3’UTR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2335P - Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma
Presenter: Jianfu Li
Session: Poster session 16
2337P - Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer
Presenter: Marina Mencinger
Session: Poster session 16
2338P - The phenotype of tumor-associated macrophages in human high-grade serous ovarian carcinoma
Presenter: Irina Larionova
Session: Poster session 16
2339P - Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
Presenter: Filippo Dall'Olio
Session: Poster session 16
2340P - T-cell immunoglobulin and mucin-domain containing molecule-3 (Tim3) in breast cancer and the impact on penetration of blood brain barrier by cancer cells
Presenter: Xiaoshan Cao
Session: Poster session 16
2341P - Novel therapeutic opportunities in metaplastic breast cancer
Presenter: Fresia Pareja
Session: Poster session 16
2342P - Single tumor cells are a novel prognostic criterion in breast cancer patients
Presenter: Liubov Tashireva
Session: Poster session 16
2343P - Evolution of circulating tumour DNA analysis in France over 5 years
Presenter: Guillaume Herbreteau
Session: Poster session 16
2345P - The possibility of programmed death-ligand 1-related immune modulation in neoadjuvant thermoradiotherapy for rectal cancer
Presenter: seihwan you
Session: Poster session 16
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16